Indian Journal of Urology Users online:899  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size
UROSCAN
Year : 2022  |  Volume : 38  |  Issue : 3  |  Page : 238-239

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?


Department of Urology, Medanta Hospital, Patna, Bihar, India

Correspondence Address:
Naveen Kumar
Department of Urology, Medanta Hospital, Patna, Bihar
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/iju.iju_81_22

Rights and Permissions



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed636    
    Printed20    
    Emailed0    
    PDF Downloaded53    
    Comments [Add]    

Recommend this journal